ClinicalTrials.gg
RecruitingNCT07726342Updated Oct 15, 2026

SMP-656 for HER2-Positive Advanced Breast Cancer

A Phase 2 interventional study of SMP-656 Injection and SMP-656 Injection in HER2-positive Breast Cancer, Metastatic Breast Cancer and Locally Advanced Breast Cancer (LABC), sponsored by Chengdu SciMount Pharmatech Co., Ltd.. Recruiting at 15 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Chengdu SciMount Pharmatech Co., Ltd. · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 15, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,936 studies in Breast Neoplasms with a site in China — 871 open to participants now, 1,068 under way, 211 of them phase 3. Breast Neoplasms · China.

Planned enrollment
1,056th of 1,525
60 · median 120
Started
2026
with 191 others
Phase 2
494 of 1,936
244 open now
Primary completion
2027-07
later than 687 of 1,067 live
Registered
1,865th of 1,936
by date

Among the 1,936 studies in Breast Neoplasms with a site in China, this one is the 1,056th largest by planned enrollment of the 1,525 interventional ones that give a count, is one of 192 that started in 2026, is one of 494 in phase 2, reaches primary completion later than 687 of the 1,067 other live ones, and was the 1,865th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

871 of the 1,936 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

865 more — sign in →

All 871 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,936 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if single-agent SMP-656 works to treat patients with HER2-positive locally advanced or metastatic breast cancer who have progressed after prior HER2-targeted topoisomerase inhibitor antibody-drug conjugate (ADC) treatment. It will also evaluate the safety of SMP-656 and identify the optimal dose for future trials. The main questions it aims to answer are:

What is the objective tumor response rate (DOR, PFS, DCR, OS) of two different dose regimens of intravenous SMP-656? What are the side effects and safety risks of these two SMP-656 dose regimens? Which dose level achieves the best balance of anti-cancer activity and tolerability? This is a randomized, open-label, dose-optimization Phase II clinical trial. Participants will be randomly assigned 1:1 to receive one of two fixed doses of SMP-656 given intravenously once every 3 weeks.

Participants will:

Complete screening tests within 28 days before the first SMP-656 infusion to confirm eligibility Receive study treatment every 3 weeks until cancer progression, intolerable side effects, withdrawal, or other stopping criteria Have regular tumor imaging scans, physical exams, vital sign checks, and blood tests to monitor tumor response and safety Attend a safety follow-up visit 30 days after the last dose of SMP-656 Complete longer-term survival follow-up after the 30-day safety check Provide optional blood and tumor tissue samples for additional research studies

Read the detailed description

This is a randomized, open-label, dose-optimization Phase II clinical trial to assess the efficacy and safety of single-agent SMP-656 in patients with HER2-positive unresectable locally advanced or metastatic breast cancer who progressed after prior HER2-targeted topoisomerase inhibitor ADC therapy.

The trial plans to enroll approximately 45-60 participants. Eligible participants must have received one prior HER2-targeted topoisomerase inhibitor ADC (e.g., DS-8201 or other ADCs with topoisomerase inhibitor payloads) and experienced disease progression (single-agent endocrine therapy excluded).

Two dose cohorts selected based on Phase I data: 2.0 mg/kg and 2.2 mg/kg. Participants will be randomized 1:1 to each dose cohort, with 15 subjects enrolled per cohort in Stage 1. An interim analysis will be conducted after Stage 1 enrollment completion:

  1. If statistically significant differences in safety/efficacy between cohorts are identified that materially impact risk-benefit assessment, the inferior cohort will be closed, and the superior cohort will accrue an additional 15 subjects to complete the trial.
  2. If no meaningful inter-cohort differences are observed, randomization will continue 1:1 with an additional 15 subjects per cohort.

The investigational product will be administered intravenously once every 3 weeks (Q3W). All participants will receive long-term treatment until the first occurrence of any of the following events: intolerable toxicity, disease progression (judged by the investigator that further treatment cannot provide clinical benefit), loss to follow-up, death, voluntary withdrawal, or study completion/early termination of the trial, whichever comes first.

A Safety Review Committee (SRC) will be established for this trial. Based on the results of interim analysis assessments, the SRC shall judge and determine the further research of each dose group, and make decisions on the key clinical trial doses.

The study consists of a screening period (from the time participants sign the informed consent form up to prior to the first study drug administration, with a maximum duration of 28 days), a treatment period (from the first study drug administration to permanent discontinuation of study drug), and a follow-up period (post-discontinuation safety follow-up and survival follow-up).

During the treatment period, all participants shall undergo tumor imaging assessments every 6 weeks (±7 days) starting from the first dose administration. Imaging assessments will not be affected by interrupted or delayed study drug administration. Investigators will assess antitumor efficacy in accordance with Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Assessments will continue until the earliest occurrence of any of the following events: disease progression, withdrawal of informed consent, loss to follow-up, death, initiation of new antitumor therapy, or trial conclusion (including trial completion and early trial termination), whichever comes first.

Safety Follow-up All participants shall complete a safety follow-up visit at 30 days ± 7 days after the last dose of the investigational product.

If the End of Treatment (EOT) visit for early discontinuation or treatment completion coincides with the scheduled safety follow-up timepoint, duplicate assessments are not required.

If the actual completion date of the early discontinuation/treatment completion (EOT) visit falls beyond the scheduled safety follow-up window due to objective reasons (e.g., delayed dosing), duplicate assessments are also not required. Failure to complete the dedicated safety follow-up in such circumstances shall not be deemed a protocol deviation (PD).

Survival Follow-up After completion of the safety follow-up, investigators will collect survival information for all participants every 3 months (±14 days) via telephone interviews, review of participants' medical records or outpatient medical files. Survival follow-up will continue until any of the following occurs: withdrawal of informed consent by the participant, loss to follow-up, death, or trial termination.

03

Conditions studied

  • HER2-positive Breast Cancer
  • Metastatic Breast Cancer
  • Locally Advanced Breast Cancer (LABC)

Browse trials for

Keywords

  • SMP-656
  • Randomized Open-Label Trial
  • HER2
  • Antibody-Drug Conjugate
  • Trastuzumab Deruxtecan resistant
  • Phase II Trial
  • Dose Optimization
  • Topoisomerase Inhibitor
  • Metastatic Breast Cancer
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in this clinical trial, understand and comply with study procedures, and provide written voluntarily.
  2. Female patients aged ≥ 18 years at the time of signing the informed consent form.
  3. Patients with or cytologically confirmed unresectable -positive locally advanced or breast cancer, regardless of hormone receptor (HR) status.
  4. HER2-positive status confirmed by testing at the study center or an accredited laboratory, where HER2 positivity is defined as IHC 3+, or IHC 2+ with positive fluorescence in situ hybridization (FISH+) results.
  5. Patients with HER2-positive locally advanced or metastatic breast cancer who have received prior treatment with one TOP inhibitor ADC targeting HER2 (e.g., DS-8201 and other ADCs with topoisomerase inhibitor payloads), and have experienced disease progression.

1) Endocrine monotherapy is excluded from the abovementioned standard therapy lines; 2) Disease recurrence occurring within 12 months following or adjuvant chemotherapy will be regarded as progression after standard therapy; 6. Have at least one measurable target lesion per the Version 1.1 (RECIST 1.1) .

7. performance status 0-1. 8. Expected survival ≥ 3 months. 9. Bone marrow, hepatic, renal and coagulation function shall be deemed adequate based on laboratory tests performed within 7 days prior to the first dose of the product. Blood transfusion or growth factor supportive therapy is prohibited within 14 days before the first administration of the investigational product:

  • Bone marrow function: (ANC) ≥ 1.5 × 10⁹/L; count (PLT) ≥ 80 × 10⁹/L; (Hb) ≥ 90 g/L;
  • Hepatic function: (AST) and alanine aminotransferase (ALT) ≤ 2.5 × (ULN); total serum (TBIL) ≤ 1.5 × ULN, with the following exceptions;
  • For participants with confirmed liver metastases: AST and/or ALT ≤ 5 × ULN;
  • For participants diagnosed with Gilbert's syndrome: TBIL ≤ 3 × ULN;
  • Serum albumin ≥ 30 g/L;
  • Renal function: (CrCL) ≥ 50 mL/min (calculated via the Cockcroft-Gault formula), OR serum creatinine ≤ 1.5 × ULN;
  • Coagulation function: (INR) ≤ 1.5 × ULN, and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.

    10. Women of (WOCBP) must agree to use highly effective or maintain abstinence from the time of informed consent signature through 6 months after the last administration of the investigational product;For WOCBP, serum pregnancy testing performed within 7 days prior to the first dose of the investigational product must yield a negative result.

Exclusion criteria

Exclusion Criteria:

  1. Patients with inflammatory breast cancer.
  2. Have received eribulin in .
  3. Have received prior treatment with an ADC with a tubulin inhibitor payload for recurrent or disease following prior treatment with an ADC with a topoisomerase inhibitor payload.
  4. Prior anti-tumor therapy consisting of utidelone or vinca alkaloids as the last regimen.
  5. Patients with a known history of severe to inetetamab, SMP-656, or any of their .
  6. Patients with meningeal metastases.
  7. Patients with active central nervous system (CNS) metastases are excluded, with the following exception: symptomatic limited to supratentorial region and/or cerebellum (i.e., no midbrain, pons, medulla oblongata or spinal cord metastases) that have received local therapy, with neurological symptoms stabilized for at least 2 weeks prior to the first dose of product, and no requirement for therapy or receiving prednisone ≤10 mg/day (or equivalent corticosteroids).
  8. Patients diagnosed with any other (other than the study tumor type) within 5 years prior to the first dose of the investigational product, except curatively treated localized malignancies such as basal cell carcinoma of the skin.
  9. History of interstitial lung disease (ILD) requiring corticosteroid intervention; current or suspected ILD; or has evidence of active pneumonia at screening; or has active radiation pneumonitis requiring ongoing medical therapy; or has other severe pulmonary disease impairing respiratory function.
  10. Patients with a clinically significant history of cardiovascular disease, including but not limited to: (1) (LVEF) \< 50%; congestive heart failure with (NYHA) functional class > 2; (2) Have experienced myocardial infarction, unstable angina, severe pericardial disease or severe myocardial disease within the previous 6 months; (3) Presence of cardiac valve regurgitation or stenosis requiring therapeutic intervention; (4) Any supraventricular or ventricular arrhythmia requiring treatment or intervention; poorly controlled malignant arrhythmias despite medication; complete left bundle branch block, second-degree or third-degree atrioventricular block; (5) > 470 ms at screening (for female participants), or known family history of long QT syndrome; (6) Uncontrolled hypertension (defined as systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg despite antihypertensive medication, or prior history of hypertensive crisis or hypertensive encephalopathy).
  11. History of arterial or venous thromboembolic events within 6 months prior to the first dose of the investigational product, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism.
  12. Participants with uncontrollable pleural effusion, pericardial effusion or ascites as judged by the Investigator, which requires repeated drainage once every two weeks or more frequently. Participants with indwelling pleural catheters are permitted to enroll.
  13. Have received within 4 weeks prior to the first dose of the investigational produc, or plan to receive live attenuated vaccines during the study.
  14. Patients with severe infection within 4 weeks prior to the first dose of the investigational product, including but not limited to bacteremia or severe pneumonia requiring hospitalization; or active infection with Grade ≥2 requiring systemic antibiotic therapy within 2 weeks before the first dose (prophylactic antibiotics excluded) .
  15. Patients meeting any of the following criteria will be excluded: patients with active or ;For patients positive for hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb), enrollment is permitted only if quantitative hepatitis B virus DNA (HBV-DNA) is below the (ULN) of the study site laboratory;For patients positive for hepatitis C antibody (HCV-Ab), enrollment is permitted only if HCV RNA is below the ULN of the study site laboratory;Positive (HIV) antibody test; active syphilis infection; active tuberculosis infection.
  16. Patients with unresolved prior anti-tumor treatment-related toxicities (alopecia excluded) remaining at Grade >1 or not recovered to baseline, except adverse events (AEs) deemed not to pose a safety risk by the Investigator.
  17. Patients with Grade ≥2 peripheral neuropathy; or prior history of Grade ≥3 neurotoxicity / peripheral neuropathy; or permanent discontinuation of previous anti-tumor treatment due to neurotoxicity or peripheral neuropathy.
  18. Patients with a history of stem cell transplantation or solid organ transplantation, or those planning to receive allogeneic stem cell transplantation or solid organ transplantation during the study.
  19. Patients who have participated in any other clinical trial within 4 weeks or 5 half-lives prior to the first dose of the investigational product, whichever is shorter.
  20. Patients who received radiotherapy within 4 weeks prior to the first dose of the investigational product are excluded, except palliative radiotherapy administered for symptom control within 2 weeks before the first dose of investigational product.
  21. Patients who received systemic anti-tumor therapy within 4 weeks prior to the first dose of the investigational product are excluded, except for the following: 1) Enrollment is permitted only if at least 6 weeks have elapsed between the completion of prior nitrosourea or mitomycin chemotherapy and the first dose of the investigational product; 2) Enrollment is allowed only if a minimum of 1 week has passed between the discontinuation of prior small-molecule targeted therapy and the first dose of the investigational product; 3) Enrollment is permitted only if a minimum of 2 weeks have elapsed between discontinuation of prior traditional Chinese medicine with anti-tumor effects and the first dose of the investigational product.
  22. articipants who have undergone major surgery within 4 weeks prior to the first dose of the investigational product, or are expected to receive major surgery during the study period (diagnostic surgery excluded); those who received diagnostic or minimally invasive surgery within 1 week before the first dose are also excluded.
  23. Patients requiring long-term treatment with corticosteroids or agents (e.g., active diseases requiring systemic therapy). Replacement therapies such as thyroxine, insulin, or physiological corticosteroid replacement for adrenal or pituitary insufficiency are permitted.
  24. Prior documented history of neurological or psychiatric disorders, including epilepsy or dementia.
  25. Female Patients who are pregnant, breastfeeding, or planning to become pregnant during the study.
  26. Patients with severe concomitant diseases that may compromise patient safety or interfere with study completion as judged by the Investigator (e.g., severe hypertension, diabetes mellitus, thyroid disorders), or any other conditions deemed inappropriate for study participation by the Investigator.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    SMP-656 2.0 mg/kg

    SMP-656 2.0 mg/kg Q3W

    Drug: SMP-656 Injection

  • Experimental
    SMP-656 2.2 mg/kg

    SMP-656 2.2 mg/kg Q3W

    Drug: SMP-656 Injection

Interventions

  • DrugSMP-656 Injection

    SMP-656 injection administered via intravenous infusion at a dose of 2.0 mg/kg once every 3 weeks (Q3W). Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death, or trial termination.

  • DrugSMP-656 Injection

    SMP-656 injection administered via intravenous infusion at a dose of 2.2 mg/kg once every 3 weeks (Q3W). Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death, or trial termination.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) assessed by Independent Review Committee (IRC)

    ORR is the percentage of evaluable patients with an IRC-assessed response of complete response (CR) or partial response (PR) per RECIST v1.1.

    Time frame: From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)

  2. Recommended Dose in Pivotal Clinical Trials

    Determination of pivotal trial recommended dose based on drug exposure, efficacy, and safety profiles across different dose levels.

    Time frame: Through study completion, up to 24 months from first dose

Secondary outcomes

  1. ORR assessed by Investigators

    Investigator-assessed ORR is the percentage of evaluable patients with a confirmed investigator-assessed response of CR or PR per RECIST v1.1.

    Time frame: From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)

  2. Duration of Response (DOR)

    DOR is the time from the date of first documented confirmed objective response (CR or PR per RECIST v1.1) until the date of disease progression or death.

    Time frame: From first confirmed objective response (CR/PR) up to 24 months from first dose

  3. Progression-Free Survival (PFS)

    PFS is the time from the date of first dose until the date of objective radiographic disease progression or death (by any cause in the absence of progression).

    Time frame: From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)

  4. Disease Control Rate (DCR)

    DCR is the investigator-assessed percentage of evaluable participants with confirmed CR (complete response), PR (partial response), or SD (stable disease) per RECIST v1.1.

    Time frame: Up to 24 months from first dose

  5. Overall Survival (OS)

    OS is the time from the date of first dose until the date of death by any cause.

    Time frame: From treatment initiation until death from any cause, assessed up to 60 months.

  6. Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) / Serious Adverse Events (SAEs)

    Frequency, type, and maximum grade of all AEs and SAEs graded per NCI CTCAE Version 6.0

    Time frame: From enrollment through 30 days after last study drug administration, up to 24 months

  7. Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer

    Maximum Plasma concentration (Cmax) of SMP-656 and total anti-HER2 antibody is assessed.

    Time frame: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).

  8. Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) of Free Eribulin Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer

    Maximum Plasma Concentration (Cmax) of free eribulin is assessed.

    Time frame: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).

  9. Pharmacokinetic Parameter Time to Maximum Serum Concentration (Tmax) Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer

    Time to maximum serum concentration (Tmax) of SMP-656 and total anti-HER2 antibody is assessed.

    Time frame: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).

  10. Pharmacokinetic Parameter Time to Maximum Serum Concentration (Tmax) of Free Eribulin Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer

    Time to maximum serum concentration (Tmax) of free eribulin is assessed.

    Time frame: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).

  11. Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer

    AUC from time zero to the last quantifiable concentration (AUC0-last) and AUC over one dosing interval (AUC0-tau) of SMP-656 and total anti-HER2 antibody are assessed.

    Time frame: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).

  12. Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of Free Eribulin Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer

    AUC from time zero to the last quantifiable concentration (AUC0-last) and AUC over one dosing interval (AUC0-tau) of free eribulin is assessed.

    Time frame: Each cycle is 21 days. Cycle 1Day 1(C1D1): before infusion (BI), end of infusion (EOI); C2D1: BI; C3D1: BI, EOI; C4D1 and C5D1: BI; all subsequent odd cycles (C7D1, C9D1, etc): BI; and 30 (±7) days after last dose (up to 24 months).

  13. Exposure-Efficacy and Exposure-Safety (E-R) Relationships

    Exposure-response (E-R) analysis evaluating correlations between exposure of conjugated SMP-656, total antibody, free eribulin and efficacy/safety endpoints.

    Time frame: Each cycle is 21 days. Exposure, efficacy and safety data are collected during Cycle 1-5 and subsequent odd maintenance cycles, at the occurrence of SAEs or Grade ≥3 TRAEs, and through 30 (±7) days following the last study dose. (up to 24 months)

  14. Exposure-Efficacy and Exposure-Safety (E-R) Relationships

    Exposure-response (E-R) analysis evaluating correlations between exposure of conjugated SMP-656, total antibody, free eribulin and efficacy/safety endpoints.

    Time frame: From Cycle 1 through all odd maintenance cycles, 30 days after last dose, and at onset of serious adverse event or Grade ≥3 treatment-related adverse event

  15. Immunogenicity of SMP-656

    Incidence and magnitude of anti-drug antibody responses to SMP-656

    Time frame: Each cycle is 21 days. Immunogenicity sampling is conducted within 1 hour pre-dose on C1D1, C2D1, C3D1, C5D1, and every 4 subsequent cycles. Additional sampling is done for SAEs/Grade ≥3 TRAEs, and 30 days after the last dose. (up to 24 months)

Other outcomes

  1. Genomic and Microenvironment Molecular Alterations Associated With SMP-656 Resistance

    Baseline and post-treatment genomic, circulating biomarker and tissue spatial microenvironment profiles of blood and tumor samples, including ctDNA, circulating proteins, exosomes, and tissue microenvironment features.

    Time frame: Baseline and end-of-treatment (EOT) visit. EOT sampling is performed within 7 days after treatment discontinuation and prior to any new antitumor therapy, up to 24 months from first dose.

  2. Multi-Omics Biomarker Profiles Correlated With Clinical Efficacy and Prognosis

    Multi-omics profiles of blood and tumor samples, including ctDNA, plasma proteomics, single-exosome profiling, tissue spatial transcriptomics/proteomics, and tissue genomic features.

    Time frame: Baseline and EOT visit. EOT sampling is performed within 7 days after treatment discontinuation and prior to any new antitumor therapy, up to 24 months from first dose.

07

Study locations

1 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 10 months after the start.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 10 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 24, 2026
StartActual
Aug 10, 2026was Jul 2026
Primary completionEst.
Jul 7, 2027
CompletionEst.
Oct 20, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
15 sites changed recruiting status (14 now not yet recruiting, 1 now recruiting)
Show 15 sites
  • The Second Affiliated Hospital of Anhui Medical University · Hefei, Chinano status→Not yet recruiting
  • Beijing Cancer Hospital · Beijing, Chinano status→Not yet recruiting
  • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, Chinano status→Recruiting
  • Sun Yat-sen University Cancer Center · Guangzhou, Chinano status→Not yet recruiting
  • The Fourth Hospital of Hebei Medical University · Shijiazhuang, Chinano status→Not yet recruiting
  • Henan Provincial People's Hospital · Zhengzhou, Chinano status→Not yet recruiting
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Chinano status→Not yet recruiting
  • Zhongnan Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
  • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University · Changsha, Chinano status→Not yet recruiting
  • Zhongda Hospital, Southeast University · Nanjing, Chinano status→Not yet recruiting
  • Liaoning Cancer Hospital & Institute · Shenyang, Chinano status→Not yet recruiting
  • Shandong Cancer Hospital and Institute · Jinan, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Xi'an Jiaotong University · Xi’an, Chinano status→Not yet recruiting
  • Sichuan Cancer Hospital & Institute · Chengdu, Chinano status→Not yet recruiting
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine · Hangzhou, Chinano status→Not yet recruiting
Oct 15, 2026
Start date
Jul 16, 2026→Aug 10, 2026 (actual)
Oct 15, 2026
Eligibility
3 inclusion criteria edited, 2 removed; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedPatients with HER2-positive locally advanced or metastatic breast cancer who have received prior treatment with one TOP inhibitor ADC targeting HER2 (e.g., DS-8201 and other ADCs with topoisomerase inhibitor payloads), and have experienced disease progression after no more than three lines of standard therapy for recurrent or metastatic disease; 1) Endocrine monotherapy is excluded from the abovementioned standard therapy lines; 2) Disease recurrence occurring within 12 months following neoadjuvant or adjuvant chemotherapy will be regarded as progression after first-line standard therapy;.
  • Edited1) Endocrine monotherapy is excluded from the abovementioned standard therapy lines; 2) Disease recurrence occurring within 12 months following neoadjuvant or adjuvant chemotherapy will be regarded as progression after first-line standard therapy; 6. Have at least one measurable target lesion per the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) ;.
  • RemovedECOG performance status 0-1;
  • RemovedExpected survival ≥ 3 months;
  • Edited7. ECOG performance status 0-1. 8. Expected survival ≥ 3 months. 9. Bone marrow, hepatic, renal and coagulation function shall be deemed adequate based on laboratory tests performed within 7 days prior to the first dose of the investigational product. Blood transfusion or growth factor supportive therapy is prohibited within 14 days before the first administration of the investigational product:
Exclusion criteria
  • EditedHave received prior treatment with ADCs carryingan ADC with a tubulin inhibitor payloadspayload for recurrent or metastatic disease; following prior treatment with an ADC with a topoisomerase inhibitor payload.
  • ChangedBefore Previous, current or suspected interstitial lung disease (ILD), drug-induced interstitial lung disease; or clinically significant active pneumonia identified at screening; or radiation pneumonitis, or other severe pulmonary disorders impairing respiratory function, which in the Investigator's judgment may interfere with the detection or management of investigational product-related pulmonary toxicity;Now History of interstitial lung disease (ILD) requiring corticosteroid intervention; current or suspected ILD; or has evidence of clinically significant active pneumonia at screening; or has active radiation pneumonitis requiring ongoing medical therapy; or has other severe pulmonary disease impairing respiratory function.
Oct 15, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionPharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer: how it is measured was reworded
  • DescriptionPharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of Free Eribulin Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer: how it is measured was reworded
Oct 15, 2026
Contact
Study contact changed: x•••@medmail.com.cn · •••1183→x•••@xilinglab.com · •••5028. See the current contact
Oct 15, 2026
Site contacts
Changed at 15 sites. See the sites
Show 15 sites
  • The Second Affiliated Hospital of Anhui Medical University · Hefei, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • Beijing Cancer Hospital · Beijing, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • Sun Yat-sen University Cancer Center · Guangzhou, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • The Fourth Hospital of Hebei Medical University · Shijiazhuang, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • Henan Provincial People's Hospital · Zhengzhou, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • Zhongnan Hospital of Wuhan University · Wuhan, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University · Changsha, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • Zhongda Hospital, Southeast University · Nanjing, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • Liaoning Cancer Hospital & Institute · Shenyang, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • Shandong Cancer Hospital and Institute · Jinan, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • The First Affiliated Hospital of Xi'an Jiaotong University · Xi’an, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • Sichuan Cancer Hospital & Institute · Chengdu, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine · Hangzhou, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    15 sites changed recruiting status (14 now not yet recruiting, 1 now recruiting)
    Show 15 sites
    • The Second Affiliated Hospital of Anhui Medical University · Hefei, Chinano status→Not yet recruiting
    • Beijing Cancer Hospital · Beijing, Chinano status→Not yet recruiting
    • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, Chinano status→Recruiting
    • Sun Yat-sen University Cancer Center · Guangzhou, Chinano status→Not yet recruiting
    • The Fourth Hospital of Hebei Medical University · Shijiazhuang, Chinano status→Not yet recruiting
    • Henan Provincial People's Hospital · Zhengzhou, Chinano status→Not yet recruiting
    • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Chinano status→Not yet recruiting
    • Zhongnan Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
    • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University · Changsha, Chinano status→Not yet recruiting
    • Zhongda Hospital, Southeast University · Nanjing, Chinano status→Not yet recruiting
    • Liaoning Cancer Hospital & Institute · Shenyang, Chinano status→Not yet recruiting
    • Shandong Cancer Hospital and Institute · Jinan, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Xi'an Jiaotong University · Xi’an, Chinano status→Not yet recruiting
    • Sichuan Cancer Hospital & Institute · Chengdu, Chinano status→Not yet recruiting
    • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine · Hangzhou, Chinano status→Not yet recruiting
    Start date Jul 16, 2026→Aug 10, 2026 (now actual)
    Eligibility 3 inclusion criteria edited, 2 removed; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatients with HER2-positive locally advanced or metastatic breast cancer who have received prior treatment with one TOP inhibitor ADC targeting HER2 (e.g., DS-8201 and other ADCs with topoisomerase inhibitor payloads), and have experienced disease progression after no more than three lines of standard therapy for recurrent or metastatic disease; 1) Endocrine monotherapy is excluded from the abovementioned standard therapy lines; 2) Disease recurrence occurring within 12 months following neoadjuvant or adjuvant chemotherapy will be regarded as progression after first-line standard therapy;.
    • Edited1) Endocrine monotherapy is excluded from the abovementioned standard therapy lines; 2) Disease recurrence occurring within 12 months following neoadjuvant or adjuvant chemotherapy will be regarded as progression after first-line standard therapy; 6. Have at least one measurable target lesion per the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) ;.
    • RemovedECOG performance status 0-1;
    • RemovedExpected survival ≥ 3 months;
    • Edited7. ECOG performance status 0-1. 8. Expected survival ≥ 3 months. 9. Bone marrow, hepatic, renal and coagulation function shall be deemed adequate based on laboratory tests performed within 7 days prior to the first dose of the investigational product. Blood transfusion or growth factor supportive therapy is prohibited within 14 days before the first administration of the investigational product:
    Exclusion criteria
    • EditedHave received prior treatment with ADCs carryingan ADC with a tubulin inhibitor payloadspayload for recurrent or metastatic disease; following prior treatment with an ADC with a topoisomerase inhibitor payload.
    • ChangedBefore Previous, current or suspected interstitial lung disease (ILD), drug-induced interstitial lung disease; or clinically significant active pneumonia identified at screening; or radiation pneumonitis, or other severe pulmonary disorders impairing respiratory function, which in the Investigator's judgment may interfere with the detection or management of investigational product-related pulmonary toxicity;Now History of interstitial lung disease (ILD) requiring corticosteroid intervention; current or suspected ILD; or has evidence of clinically significant active pneumonia at screening; or has active radiation pneumonitis requiring ongoing medical therapy; or has other severe pulmonary disease impairing respiratory function.
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionPharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer: how it is measured was reworded
    • DescriptionPharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of Free Eribulin Following Treatment With SMP-656 in Participants With HER2-Positive Locally Advanced or Metastatic Breast Cancer: how it is measured was reworded
    Contact Study contact changed: x•••@medmail.com.cn · •••1183→x•••@xilinglab.com · •••5028. See the current contact
    Site contacts Changed at 15 sites. See the sites
    Show 15 sites
    • The Second Affiliated Hospital of Anhui Medical University · Hefei, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • Beijing Cancer Hospital · Beijing, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • Sun Yat-sen University Cancer Center · Guangzhou, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • The Fourth Hospital of Hebei Medical University · Shijiazhuang, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • Henan Provincial People's Hospital · Zhengzhou, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • Zhongnan Hospital of Wuhan University · Wuhan, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University · Changsha, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • Zhongda Hospital, Southeast University · Nanjing, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • Liaoning Cancer Hospital & Institute · Shenyang, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • Shandong Cancer Hospital and Institute · Jinan, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • The First Affiliated Hospital of Xi'an Jiaotong University · Xi’an, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • Sichuan Cancer Hospital & Institute · Chengdu, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine · Hangzhou, ChinaContact d•••@xilinglab.com · •••0819→x•••@xilinglab.com · •••5028
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07726342
Lead sponsor
Chengdu SciMount Pharmatech Co., Ltd.
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Aug 10, 2026
Primary completion
Jul 7, 2027 (estimated)
Completion
Oct 20, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Xiaoxia Li
Contact
xiaoxial@xilinglab.com
86-15308035028

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion